Hims & Hers unveiled a partnership with GRAIL that allows their Labs customers to add on the Galleri test, a blood test that screens for a signal shared by more than 50 types of cancer, at a discounted price. On the same day, President Donald Trump signed the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act into law, outlining a pathway for Medicare coverage once multi-cancer early detection tests are approved by the FDA.
According to Dr. Pat Carroll, chief medical officer at Hims & Hers, the company recognized the need for an early detection offering on its Labs platform. “We really felt there was a need for some type of early detection offering on Labs. It’s not that we’re going to be treating or actually doing a further workup for folks who come up with positive signals, but we can actually make an impact in terms of earlier diagnoses and referring them to appropriate providers,” Carroll said. Hims & Hers has trained a small provider group intentionally to handle results, particularly positive signals. Results from GRAIL are expected within 15 hours, after which Hims & Hers contacts the patient to walk through what the result means. If a positive signal appears, the company provides customers with all necessary information to share with their primary care provider, and GRAIL’s Advocacy Network can connect customers who cannot access their primary care provider to answer questions and provide referrals.
Physicians expressed both excitement and caution about multi-cancer early detection tests. Dr. Carmen Guerra, a primary care physician at UPenn Medicine, noted that payers take official industry guidelines and Medicare decisions into account when deciding whether to reimburse. However, gaps exist—in Pennsylvania, where guidelines changed back in 2018 recommending colorectal cancer screening starting at age 45, some payers gave patients and doctors difficulty for having a colonoscopy at that age. The American Cancer Society recommends primary care physicians wait for more evidence before bringing up these tests to patients, though if patients seek them out independently, Guerra recommends encouraging participation in randomized control trials.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.newsweek.com/hims-hers-adds-cancer-screening-cmo-shares-the-details-access-health-11473416